0.34
-6.53%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Reviva Pharmaceuticals Holdings
From its filings with the US Securities and Exchange Commission
Reviva Pharmaceuticals Holdings is based in Cupertino, California and is incorporated in Delaware. Its shares trade on OTC under the ticker RVPH. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $19.9m. At that date it held total assets of $15.9m and shareholders' equity of $8.6m.
All references in this report to “Reviva,” the “Company,” “we,” “us,” or “our” mean Reviva Pharmaceuticals Holdings, Inc. and its subsidiaries unless we state otherwise, or the context otherwise indicates.
Old Reviva was incorporated in the state of Delaware on May 1, 2006, and its subsidiary, Reviva Pharmaceuticals India Pvt. Ltd., was incorporated on December 23, 2014. Tenzing was formed pursuant to the laws of the British Virgin Islands on March 20, 2018.
We are a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing significant unmet medical needs and burdens to society, patients, and their families. Our current pipeline focuses on the central nervous system, inflammatory, and cardiometabolic diseases. We use a chemical genomics driven technology platform and proprietary chemistry to develop new medicines. Our pipeline currently has two drug candidates, brilaroxazine (RP5063) and RP1208 (Figure 1). Both are new chemical entities discovered in-house. We have been granted composition of matter patents for both brilaroxazine and RP1208 in the United States (U.S.), Europe, and several other countries.
Quoted from its 10-K, filed 30 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 18 Oct 2018
- Employees
- 10
- Website
- revivapharma.com ↗
- Head office
- 10080 N WOLFE ROAD, CUPERTINO, CA, 95014
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Parag SaxenaIndependent Chairman of the Board$87,359
- Dr. Laxminarayan BhatPresident, Chief Executive Officer, Director, since 2020$607,500
- Mr. Narayan PrabhuChief Financial Officer$404,950
- Mr. Leslie FuntleyderIndependent Director$68,359
- Dr. Richard MargolinIndependent Director$62,109
- Mr. Purav PatelIndependent Director$70,859
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Reviva Pharmaceuticals employs ten full-time staff members in Cupertino.
- The company focuses on unmet medical needs in therapeutics.
- Brilaroxazine targets multiple neuropsychiatric indications like schizophrenia and ADHD.
Weaknesses
- The firm has only ten employees for its pipeline.
- RP1208 development status remains unclear in the provided facts.
- Reviva is a clinical-stage company without commercial products yet.
Opportunities
- Brilaroxazine can treat respiratory indications like pulmonary arterial hypertension.
- RP5063 offers potential for idiopathic pulmonary fibrosis treatment.
- Development for Alzheimer’s disease symptoms expands the therapeutic scope.
Threats
- Competitors may develop superior treatments for neuropsychiatric disorders.
- Clinical trial failures could halt brilaroxazine development progress.
- Regulatory hurdles might delay approval for new drug candidates.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.